J
Jonathan S. Serody
Researcher at University of North Carolina at Chapel Hill
Publications - 218
Citations - 10616
Jonathan S. Serody is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Graft-versus-host disease & Transplantation. The author has an hindex of 54, co-authored 199 publications receiving 8564 citations. Previous affiliations of Jonathan S. Serody include Duke University & UNC Health Care.
Papers
More filters
Journal ArticleDOI
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.
Yuanzeng Min,Kyle C. Roche,Shaomin Tian,Michael J. Eblan,Karen P. McKinnon,Joseph M. Caster,Shengjie Chai,Laura E. Herring,Longzhen Zhang,Tian Zhang,Joseph M. DeSimone,Joel E. Tepper,Benjamin G. Vincent,Jonathan S. Serody,Andrew Z. Wang +14 more
TL;DR: It is shown that AC-NPs deliver tumour-specific proteins to antigen-presenting cells (APCs) and significantly improve the efficacy of αPD-1 (anti-programmed cell death 1) treatment using the B16F10 melanoma model, generating up to a 20% cure rate compared with 0% without AC- NPs.
Journal ArticleDOI
Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13.
Steven L. Highfill,Paulo C. Rodriguez,Qing Zhou,Christine A. Goetz,Brent H. Koehn,Rachelle G. Veenstra,Patricia A. Taylor,Angela Panoskaltsis-Mortari,Jonathan S. Serody,David H. Munn,Jakub Tolar,Augusto C. Ochoa,Bruce R. Blazar +12 more
TL;DR: MDSC-IL-13 and pegylated form of human arginase-1 represent novel strategies to prevent GVHD that can be clinically translated.
Journal ArticleDOI
L-Selectinhi but not the L-selectinlo CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection
Patricia A. Taylor,Angela Panoskaltsis-Mortari,Jessica M. Swedin,Philip J. Lucas,Ronald E. Gress,Bruce L. Levine,Carl H. June,Jonathan S. Serody,Bruce R. Blazar +8 more
TL;DR: In this paper, a direct comparison of LSEL(hi) and LSel(lo) Tregs for GVHD inhibition and for the promotion of allogeneic BM engraftment was provided.
Journal ArticleDOI
Leukocyte migration and graft-versus-host disease
TL;DR: Chemokine and chemokine receptor interactions and adhesion molecules that have been shown to play roles in effector cell migration in experimental GVHD models are discussed and a potential model for the role of chemokines during the activation phase of GV HD is discussed.
Journal ArticleDOI
In vitro–differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations
Michael J. Carlson,Michelle L. West,James M. Coghill,Angela Panoskaltsis-Mortari,Bruce R. Blazar,Jonathan S. Serody +5 more
TL;DR: It is demonstrated that a highly purified population of TH17 cells is capable of inducing lethal GVHD, hallmarked by extensive pathologic cutaneous and pulmonary lesions and differential roles for tumor necrosis factor-alpha (TNF-alpha) and IL-17A in the clinical manifestations of GV HD induced by TH17 Cells.